Use of Neuromuscular Blocking Agents and Neuromuscular Monitoring in 7 Danish Teaching Hospitals - a Cross-sectional Study
Overview
- Phase
- Not Applicable
- Intervention
- Rocuronium
- Conditions
- Neuromuscular Blockade
- Sponsor
- Jakob Louis Thomsen
- Enrollment
- 30430
- Locations
- 1
- Primary Endpoint
- Number of Participants With and Without Objective Neuromuscular Monitoring (Acceleromyography) in Cases Receiving a Non-depolarizing Neuromuscular Blocking Agent (NMBA) (Yes/no)
- Status
- Completed
- Last Updated
- 6 years ago
Overview
Brief Summary
Aim: To explore
- the frequency of use of objective neuromuscular monitoring for assessment of depth of neuromuscular blockade in general anaesthesia
- the incidence of residual neuromuscular blockade, and
- the timing of reversal of the neuromuscular blockade at the end of anaesthesia.
We will collect data from 7 Danish anaesthesia departments, using data from the Anaesthesia Information Management System (AIMS).
Investigators
Jakob Louis Thomsen
MD
Herlev Hospital
Eligibility Criteria
Inclusion Criteria
- •Patients who received general anaesthesia with neuromuscular blockade in one of the 7 hospitals providing data for the study in the last 18 months up until the time of data collection
Exclusion Criteria
- Not provided
Arms & Interventions
Eligible patients
Patients ≥15 years of age who received general anaesthesia with neuromuscular blockade in the last 18 months up until the time of data collection. Patients, who are eligible more than once, i.e. undergoing general anaesthesia on more than one occasion, will be included in the analyses as a case for every general anaesthetic received.
Intervention: Rocuronium
Eligible patients
Patients ≥15 years of age who received general anaesthesia with neuromuscular blockade in the last 18 months up until the time of data collection. Patients, who are eligible more than once, i.e. undergoing general anaesthesia on more than one occasion, will be included in the analyses as a case for every general anaesthetic received.
Intervention: Succinylcholine
Eligible patients
Patients ≥15 years of age who received general anaesthesia with neuromuscular blockade in the last 18 months up until the time of data collection. Patients, who are eligible more than once, i.e. undergoing general anaesthesia on more than one occasion, will be included in the analyses as a case for every general anaesthetic received.
Intervention: Cisatracurium
Eligible patients
Patients ≥15 years of age who received general anaesthesia with neuromuscular blockade in the last 18 months up until the time of data collection. Patients, who are eligible more than once, i.e. undergoing general anaesthesia on more than one occasion, will be included in the analyses as a case for every general anaesthetic received.
Intervention: Mivacurium
Eligible patients
Patients ≥15 years of age who received general anaesthesia with neuromuscular blockade in the last 18 months up until the time of data collection. Patients, who are eligible more than once, i.e. undergoing general anaesthesia on more than one occasion, will be included in the analyses as a case for every general anaesthetic received.
Intervention: Objective neuromuscular monitoring (acceleromyography)
Eligible patients
Patients ≥15 years of age who received general anaesthesia with neuromuscular blockade in the last 18 months up until the time of data collection. Patients, who are eligible more than once, i.e. undergoing general anaesthesia on more than one occasion, will be included in the analyses as a case for every general anaesthetic received.
Intervention: Sugammadex
Eligible patients
Patients ≥15 years of age who received general anaesthesia with neuromuscular blockade in the last 18 months up until the time of data collection. Patients, who are eligible more than once, i.e. undergoing general anaesthesia on more than one occasion, will be included in the analyses as a case for every general anaesthetic received.
Intervention: Neostigmine
Outcomes
Primary Outcomes
Number of Participants With and Without Objective Neuromuscular Monitoring (Acceleromyography) in Cases Receiving a Non-depolarizing Neuromuscular Blocking Agent (NMBA) (Yes/no)
Time Frame: in the period from induction of anaesthesia to termination of anaesthesia, usually 2 hours
Number of Participants With and Without Objective Neuromuscular Monitoring (Acceleromyography) in Cases Receiving a Depolarizing NMBA (Succinylcholine) (Yes/no)
Time Frame: in the period from induction of anaesthesia to termination of anaesthesia, usually 2 hours
Secondary Outcomes
- Last Recorded Train-of-four (TOF) Ratio Before Tracheal Extubation or Removal of Supraglottic Airway Device in Patients Receiving a Non-depolarizing NMBA(in the period from induction of anaesthesia to termination of anaesthesia, usually 2 hours)
- Number of Participants With and Without Administration of Sugammadex in Cases Receiving a Non-depolarizing NMBA (Yes/no)(in the period from induction of anaesthesia to discharge from the post-anaesthesia care unit, usually 5 hours)
- Number of Participants With and Without Administration of Neostigmine in Cases Receiving a Non-depolarizing NMBA (Yes/no)(in the period from induction of anaesthesia to discharge from the post-anaesthesia care unit, usually 5 hours)
- Time in Minutes From Tracheal Extubation or Removal of Supraglottic Airway Device to Discharge From Post-anaesthesia Care Unit in Cases Involving a Non-depolarizing NMBA With and Without Neuromuscular Monitoring, Respectively(in the period from induction of anaesthesia to discharge from the post-anaesthesia care unit, usually 180 minutes)
- Number of Participants With and Without Mild Oxygen Desaturation (<90%, But >80%) in Cases Receiving a Non-depolarizing NMBA(in the period between tracheal extubation or removal of supraglottic airway device and discharge from post-anaesthesia care unit, assessed up to 24 hours)
- Number of Participants With and Without Severe Oxygen Desaturation (<80%) in Cases Receiving a Non-depolarizing NMBA(in the period between tracheal extubation or removal of supraglottic airway device and discharge from post-anaesthesia care unit, assessed up to 24 hours)